Photo of Mark Fleisher M.D.

Mark Fleisher M.D.

Gastroenterologist Encore Borland Groover Clinical Research
Clinical Research Location 4800 Belfort Road Jacksonville FL 32256 Contact Research: 9046800871

Biography

Dr. Fleisher came to Borland Groover in 1998. Dr. Fleisher completed his medical training at Lenox Hill Hospital in New York City. Dr. Fleisher has published and presented at national meetings on new treatments in the management of inflammatory bowel disease. He is presently studying new treatment agents in the management of inflammatory bowel disease and is an active speaker nationally in IBD. In addition, he started the first annual meeting for patients in the Jacksonville area suffering with IBD. Dr. Fleisher is the director of Borland Groover’s Infusion Center.

Participate in Current Trials


Crohn’s Disease

 

 


Ulcerative Colitis

 

 

Contact Research


Postgraduate Education
1994 – 1996
Gastroenterology Fellowship
Lenox Hill Hospital
1990 – 1994
Residency, Internal Medicine
Lenox Hill Hospital
RESEARCH TRAINING:
11/26/2018 Medidata Classic Rave EDC Essentials for Investigators1/9/2018 CITI Good Clinical Practice Course4/27/2016 TransCelerate ICH GCP4/25/2014 TransCelerate ICH GCP1/22/2013 J&J GCO Investigator Rave Training Version 3.0
RESEARCH EXPERIENCE:

Principal Investigator:2019-Present Medtronic MDT18014 SODA, Gastrointestinal Disorder2019-Present AbbVie M14-533, Ulcerative Colitis2019-Present AbbVie M14-675, Ulcerative Colitis2019-Present AbbVie M14-234, Ulcerative Colitis2018-Present AbbVie M14-430, Crohn’s Disease2018-Present AbbVie M14-431, Crohn’s Disease2018-Present AbbVie M14-433, Crohn’s Disease2018-Present Eli Lilly I6T-MC-AMAP, Ulcerative Colitis2017-Present Medtronic COVSBCC0549 “BLINK”2017-Present Shire SHP-647-302, Ulcerative Colitis2017-Present Shire SHP-647-303, Ulcerative Colitis2017-Present Shire SHP-647-304, Ulcerative Colitis2016-Present Eli Lilly I6T- MC-AMAC, Ulcerative Colitis2016 Boehringer Ingelheim 1297.4, Crohn’s Disease2016 Prometheus/Nestle 13.06.CLI, Crohn’s Disease2016 Medtronic COVGIC20543 “TOPAZ”, Colon Capsule2016 Allergan D5170C00002, Crohn’s Disease2016 Prometheus 15IBS01, Chronic Diarrhea

2015 Celgene GED-0301-CD-001, Crohn’s Disease

2015 Roche GA29144, Crohn’s Disease

2015 Roche GA29145, Crohn’s Disease OLE

2014 Roche GA29102, Ulcerative Colitis

2014 Roche GA28950, Ulcerative Colitis

2014 Roche GA28951, Ulcerative Colitis OLE

2013 Amgen 20110232, Crohn’s Disease

2013 Amgen 20110166, Ulcerative Colitis

2013 Medtronic MA-209, Crohn’s Disease

2013 Redhill Bio RHB-104-01, Crohn’s Disease

2012 Janssen CNTO1275CRD3001 “UNITI 1”, Crohn’s Disease

2012-2019 Janssen CNTO1275CRD3003 “IMUNITI”, Crohn’s Disease

2012 Janssen CNTO1275CRD3002 “UNITI 2”, Crohn’s Disease

2007 Janssen C0524T18, Ulcerative Colitis

2007 Janssen C0524T16, Ulcerative Colitis

2005 Janssen C0168T67 “SONIC”, Crohn’s Disease

2004 Janssen C0379T07, Crohn’s Disease

Sub-Investigator:

2020-Present Allakos AK002-014, Eosinophilic Esophagitis

2020-Present Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

2020-Present Allakos AK002-019, Eosinophilic Gastrointestinal Diseases

2020-Present Adare SP-1011-003, Eosinophilic Esophagitis

2018-2019 Enanta EDP305-101, NASH

2018-2020 Shire SHP621-302, Eosinophilic Esophagitis

2018-2020 Shire SHP621-301, Eosinophilic Esophagitis

2017-2019 Pfizer C1171002, NASH

2016-2019 Novartis CLJN452A2202, Liver Disease

2016 SERES-101, Ulcerative Colitis

2014 Alvine ALV003-1221, Celiac Disease

2014 Vibrant 179CLD, Constipation

2013 Allergan D5170C00001, Crohn’s Disease

2012 Braintree BLI800-440, Bowel Cleansing Treatments

2011 Coronado CNDO 201-003, Crohn’s Disease

2011 Coronado CNDO 201-002, Crohn’s Disease

2008 Inflabloc CL-C002-00, Crohn’s Disease

2003 Facet Biotech DAC-1008, Ulcerative Colitis

2004 Biogen AN100226-CD301, Crohn’s Disease

2005 Biogen ELN100226-CD351, Crohn’s Disease

2004 Biogen AN100226-CD303, Crohn’s Disease

2003 Biogen ELN100226-CD306, Crohn’s Disease

2005 Infabloc Pharmaceuticals CL-C002-00, Crohn’s Disease

2003 Ionis Pharmaceuticals ISIS 2302-CS20, Crohn’s Disease

Publications

Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study).

Cash BD, Fleisher MR, Fern S, Rajan E, Haithcock R, Kastenberg DM, Pound D, Papageorgiou NP, Fernández-Urién I, Schmelkin IJ, Rex DK.

Gut. 2020 Dec 18:gutjnl-2020-322578. doi: 10.1136/gutjnl-2020-322578. Online ahead of print.

PMID: 33443017

 

Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn’s disease: a multicentre, prospective study.

Bruining DH, Oliva S, Fleisher MR, Fischer M, Fletcher JG; BLINK study group.

BMJ Open Gastroenterol. 2020 Jun;7(1):e000365. doi: 10.1136/bmjgast-2019-000365.

PMID: 32499275

 

Utility of video capsule endoscopy for longitudinal monitoring of Crohn’s disease activity in the small bowel: a prospective study.

Melmed GY, Dubinsky MC, Rubin DT, Fleisher M, Pasha SF, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou NP, Leighton JA.

Gastrointest Endosc. 2018 Dec;88(6):947-955.e2. doi: 10.1016/j.gie.2018.07.035. Epub 2018 Aug 4.

PMID: 30086261

 

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG.

Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018 Feb 26.

PMID: 29484571

 

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.

N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.

PMID: 27959607

 

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029. Epub 2014 Jan 27.

PMID: 24480677

 

Among giants.

Fleisher MR.

Inflamm Bowel Dis. 2013 Sep;19(10):E82. doi: 10.1097/MIB.0b013e318299c9aa.

PMID: 23846490

 

Infliximab, azathioprine, or combination therapy for Crohn’s disease.

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group.

N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.

PMID: 20393175

 

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease.

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn’s Disease Study Group.

Gastroenterology. 2008 Oct;135(4):1130-41. doi: 10.1053/j.gastro.2008.07.014. Epub 2008 Jul 17.

PMID: 18706417

 

Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn’s disease and ulcerative colitis.

Warman JI, Korelitz BI, Fleisher MR, Janardhanam R.

J Clin Gastroenterol. 2003 Sep;37(3):220-5. doi: 10.1097/00004836-200309000-00006.

PMID: 12960720

 

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.

Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR.

Am J Gastroenterol. 2003 Aug;98(8):1821-6. doi: 10.1111/j.1572-0241.2003.07581.x.

 

Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.

Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW.

Am J Gastroenterol. 1999 Nov;94(11):3248-53. doi: 10.1111/j.1572-0241.1999.01530.x

Crohn’s disease and acute leukocytoclastic vasculitis of skin.

Zlatanic J, Fleisher M, Sasson M, Kim P, Korelitz BI.

Am J Gastroenterol. 1996 Nov;91(11):2410-3.

 

Lending a hand.

Fleisher MR.

Nursing. 1994 Jul;24(7):32T.

PMID: 8022566

 

A piece of my mind. Hands on.

Fleisher MR.

JAMA. 1994 Mar 2;271(9):642. doi: 10.1001/jama.271.9.642.

PMID: 8309010

Abstracts

A Multicenter, Randomized Phase 2a Study of Human Monoclonal Antibody to IL-12/23p40 (CNTO 1275) in Patients With Moderately to Severe Active Crohn’s Disease. Plenary Session, DDW 2007

Safety of Infliximab with Previously Treated Neoplasms. Poster Presentation, DDW 2003

Steroids Versus Infliximab: Efficacy and Swiftness of Induction to Remission. Poster Presentation, DDW 2003

Infliximab: Is it a 5-ASA and Antibiotics Sparing Drug in Crohn’s Disease? Poster Presentation, DDW 2003

Infliximab in the Treatment of IBD-Associated Psoriasis and Psoriasis-Associated IBD. Poster Presentation, ACG 2002

Collagenous Colitis: Experiences of a Large Community-Based Practice. Poster Presentation, ACG 2002

Successful Treatment of IBD-Associated Pyoderma Gangrenosum with Infliximab. Poster Presentation, DDW 2002

Antinuclear Antibody and Rheumatoid Factor Expression in IBD Patients During Severe Presentations. Poster Presentation, DDW 2002

Infliximab in the Treatment of Steroid Refractory Erythema Nodosum of IBD. Poster Presentation, DDW 2002

A Continuum of the Aspiration Technique in Biliary Type 3 Sphincter of Oddi Manometry Patients and the Incidence of Pancreatitis. Poster Presentation, DDW 2002

Infliximab in the Treatment of Crohn’s Disease Complicated by Granuloma Annulare. Poster Presentation, AAD National Conference 2001

REMICADEÒ (Infliximab) in the Management of Pyoderma Gangrenosum. Poster Presentation, AAD National Conference 2001

Infliximab in the Treatment of Steroid-Naïve Ulcerative Colitis. Poster Presentation, ACG National Conference 2001

Infliximab in the Treatment of Crohn’s Disease: Is It a Steroid Sparing Agent or a Steroid Replacing Agent? Poster Presentation, ACG National Conference 2001

A Case Report: Infliximab in the Treatment of Bechet’s Syndrome. Poster Presentation, ACG National Conference 2001

Remicade in the Treatment of Refractory Extraintestinal Manifestations of Crohn’s Disease. Poster Presentation, DDW 2001

Malignant Neoplasms Subsequent to Treatment of Inflammatory Bowel Disease with 6 – Mercaptopurine. Plenary Session Presentation ACG National Conference 1996

Intravenous ACTH versus Hydrocortisone in the Treatment of Hospitalized Patients with Crohn’s Disease. Plenary Session Presentation ACG National Conference 1995

Hypokalemia Due to Intravenous Hydrocortisone versus ACTH in the Treatment of Hospitalized Patients with Crohn’s Disease. Poster Presentation ACG National Conference 1995